Loading...
Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodila...
Saved in:
| Published in: | Allergy |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7820970/ https://ncbi.nlm.nih.gov/pubmed/33010038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14611 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|